← back to search

William Rosenberg

Center for Digestive and Liver Diseases · GB
Area of research
Hepatology · Epidemiology
Research interest
Research interests include Liver Disease Diagnosis and Treatment, Hepatitis C virus research, Liver Disease and Transplantation, and Hepatitis B Virus Studies.
h-index
64
citations
37,615
works
506
NIH funding
primary concept
Medicine
email

Recent publications

Evaluation of Liver Fibrosis Change After DAA-induced Cure of Hepatitis C in Participants With and Without HIV: ACTG A5320 Viral Hepatitis C Infection Long-term Cohort Study (VHICS).
2026cited by 0position: contributordoi
Usefulness of plasma bile acid profile as a prognostic biomarker for drug-induced liver injury.
2026cited by 0position: contributordoi
IL-1 Signal Inhibition in Alcohol-Related Hepatitis: A Randomized, Double-Blind, Placebo-Controlled Trial of Canakinumab.
2025cited by 14position: contributordoi
Direct-acting antiviral treatment outcomes in people infected with endemic compared to epidemic hepatitis C virus subtypes in England.
2025cited by 1position: contributordoi
Qualitative evaluation of the barriers and facilitators to a retrospective hepatitis C virus patient re-engagement exercise in England .
2025cited by 0position: contributordoi
Enhanced liver fibrosis test facilitates stratification of people with alcohol use disorder in primary care.
2025cited by 0position: contributordoi
The Camden and Islington Viral Hepatitis Identification Tool (CIVHIT): Use of a Clinical Database Case-Finding Tool for Hepatitis B, Hepatitis C and HIV in Primary Care.
2025cited by 0position: contributordoi
Adjusted estimate of the prevalence of hepatitis delta virus in 25 countries and territories.
2024cited by 68position: contributordoi
IL-1 Signal Inhibition in Alcohol-Related Hepatitis: A Randomized, Double-Blind, Placebo-Controlled Trial of Canakinumab
Clinical Gastroenterology and Hepatology 2024cited by 21position: middledoi
Progress is impossible without change: understanding the evolving nomenclature of steatotic liver disease and its effect on hepatology practice.
2024cited by 16position: contributordoi
Top ten research priorities for alcohol use disorder and alcohol-related liver disease: results of a multistakeholder research priority setting partnership.
2024cited by 4position: contributordoi
Results from a retrospective case finding and re-engagement exercise for people previously diagnosed with hepatitis C virus to increase uptake of directly acting antiviral treatment.
2024cited by 2position: contributordoi
Hepatitis D double reflex testing of all hepatitis B carriers in low-HBV- and high-HBV/HDV-prevalence countries
Journal of Hepatology 2023cited by 61position: middledoi
Hepatitis D double reflex testing of all hepatitis B carriers in low-HBV- and high-HBV/HDV-prevalence countries.
2023cited by 50position: contributordoi
Longitudinal Assessment of the Enhanced Liver Fibrosis Score in the Era of Contemporary HIV and Hepatitis C Virus Treatment.
2023cited by 8position: contributordoi
Exploring changing attitudes to non-invasive liver fibrosis tests in secondary care pathways: comparison of two national surveys.
2023cited by 8position: contributordoi
A scoping review of media campaign strategies used to reach populations living with or at high risk for Hepatitis C in high income countries to inform future national campaigns in the United Kingdom.
2023cited by 5position: contributordoi
Investigation of Serum Markers of Hepatic Fibrosis in Equids.
2023cited by 4position: contributordoi
Identification of liver disease: why and how.
2022cited by 24position: contributordoi
An entropic safety catch controls hepatitis C virus entry and antibody resistance.
2022cited by 10position: contributordoi
Towards collaborative management of non-alcoholic fatty liver disease: a 'real-world' pathway for fibrosis risk assessment in primary care.
2022cited by 5position: contributordoi
The fate of indeterminate liver lesions: What proportion are precursors of hepatocellular carcinoma?
2022cited by 4position: contributordoi
Author response: An entropic safety catch controls hepatitis C virus entry and antibody resistance
2022cited by 0position: contributordoi
Therapeutic Potential of TLR8 Agonist GS-9688 (Selgantolimod) in Chronic Hepatitis B: Remodeling of Antiviral and Regulatory Mediators.
2021cited by 73position: contributordoi
Systematic review: Accuracy of the enhanced liver fibrosis test for diagnosing advanced liver fibrosis and cirrhosis.
2021cited by 29position: contributordoi
Circulating Macrophage Activation Markers Predict Transplant-Free Survival in Patients With Primary Sclerosing Cholangitis.
2021cited by 19position: contributordoi
Fluctuating biomarkers in primary sclerosing cholangitis: A longitudinal comparison of alkaline phosphatase, liver stiffness, and ELF.
2021cited by 18position: contributordoi
The Enhanced Liver Fibrosis test maintains its diagnostic and prognostic performance in alcohol-related liver disease: a cohort study.
2021cited by 17position: contributordoi
Relationship of ELF and PIIINP With Liver Histology and Response to Vitamin E or Pioglitazone in the PIVENS Trial.
2021cited by 17position: contributordoi
Mortality and AIDS-defining events among young people following transition from paediatric to adult HIV care in the UK.
2021cited by 17position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

· 14 papers (2019–2026)Emmanuel A. Tsochatzis · Odense University Hospital8 papers (2019–2024)Alison Rodger · Royal Free London NHS Foundation Trust4 papers (2019–2021)Julie Parkes · University of Southampton4 papers (2012–2016)Stuart McPherson · University of Sheffield3 papers (2021–2024)John Dillon · Mayo Clinic3 papers (2022–2024)Sema Mandal · Public Health England3 papers (2019–2021) · 2 papers (2016–2016)Paul R. Grant · Royal London Hospital2 papers (2016–2016) · 2 papers (2013–2014)C Sabin · University College London2 papers (2021–2025)Joe Grove · University College London2 papers (2022–2022)Mala K. Maini · Technical University of Munich2 papers (2020–2021)Javier Crespo · Instituto de Salud Carlos III2 papers (2023–2024)Mphatso D Kalemera · Imperial College London2 papers (2022–2022)Stephen Ryder · Imperial College Healthcare NHS Trust2 papers (2021–2023)Christopher J R Illingworth · MRC University of Glasgow Centre for Virus Research2 papers (2022–2022)Andrew Yeoman · Aneurin Bevan University Health Board2 papers (2022–2023) · 2 papers (2022–2023)Homie Razavi · Institute of Medical Sciences2 papers (2023–2024)